308 related articles for article (PubMed ID: 31711435)
21. Screening test results associated with cancer diagnoses in 287 women with cervical squamous cell carcinoma.
Li Z; Austin RM; Guo M; Zhao C
Arch Pathol Lab Med; 2012 Dec; 136(12):1533-40. PubMed ID: 22900617
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the analytical and clinical performances of Abbott RealTime High Risk HPV, Hybrid Capture 2, and DNA Chip assays in gynecology patients.
Park S; Kang Y; Kim DG; Kim EC; Park SS; Seong MW
Diagn Microbiol Infect Dis; 2013 Aug; 76(4):432-6. PubMed ID: 23791386
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic performance of the E6/E7 mRNA-based Optimygene HR-HPV RT-qDx assay for cervical cancer screening.
Wang HY; Kim H; Park KH
Int J Infect Dis; 2019 Jan; 78():22-30. PubMed ID: 30248464
[TBL] [Abstract][Full Text] [Related]
24. Validation of a Human Papillomavirus (HPV) DNA Cervical Screening Test That Provides Expanded HPV Typing.
Demarco M; Carter-Pokras O; Hyun N; Castle PE; He X; Dallal CM; Chen J; Gage JC; Befano B; Fetterman B; Lorey T; Poitras N; Raine-Bennett TR; Wentzensen N; Schiffman M
J Clin Microbiol; 2018 May; 56(5):. PubMed ID: 29491018
[TBL] [Abstract][Full Text] [Related]
25. Primary HPV testing: a proposal for co-testing in initial rounds of screening to optimise sensitivity of cervical cancer screening.
Herbert A
Cytopathology; 2017 Feb; 28(1):9-15. PubMed ID: 27005867
[TBL] [Abstract][Full Text] [Related]
26. Analytical evaluation of the PapilloCheck test, a new commercial DNA chip for detection and genotyping of human papillomavirus.
Dalstein V; Merlin S; Bali C; Saunier M; Dachez R; Ronsin C
J Virol Methods; 2009 Mar; 156(1-2):77-83. PubMed ID: 19041893
[TBL] [Abstract][Full Text] [Related]
27. HPV for cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer.
Ogilvie GS; Krajden M; van Niekerk D; Smith LW; Cook D; Ceballos K; Lee M; Gentile L; Gondara L; Elwood-Martin R; Peacock S; Stuart G; Franco EL; Coldman AJ
Int J Cancer; 2017 Jan; 140(2):440-448. PubMed ID: 27685757
[TBL] [Abstract][Full Text] [Related]
28. Uptake of co-testing with HPV and cytology for cervical screening: A population-based evaluation in the United States.
Cuzick J; Du R; Adcock R; Kinney W; Joste N; McDonald RM; English K; Torres SM; Saslow D; Wheeler CM;
Gynecol Oncol; 2021 Sep; 162(3):555-559. PubMed ID: 34253387
[TBL] [Abstract][Full Text] [Related]
29. Assessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework.
Xu L; Oštrbenk A; Poljak M; Arbyn M
J Clin Virol; 2018 Jan; 98():37-42. PubMed ID: 29241150
[TBL] [Abstract][Full Text] [Related]
30. Prevalence and determinants of cervical cancer screening with a combination of cytology and human papillomavirus testing.
Fokom Domgue J; Cunningham SA; Yu RK; Shete S
Ann Epidemiol; 2019 Aug; 36():40-47. PubMed ID: 31320153
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic accuracy of high-risk HPV genotyping in women with high-grade cervical lesions: evidence for improving the cervical cancer screening strategy in China.
Xu H; Lin A; Shao X; Shi W; Zhang Y; Yan W
Oncotarget; 2016 Dec; 7(50):83775-83783. PubMed ID: 27626178
[TBL] [Abstract][Full Text] [Related]
32. Clinical experience with the Cervista HPV HR assay: correlation of cytology and HPV status from 56,501 specimens.
Youens KE; Hosler GA; Washington PJ; Jenevein EP; Murphy KM
J Mol Diagn; 2011 Mar; 13(2):160-6. PubMed ID: 21354050
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of human papillomavirus genotype among Moroccan women during a local screening program.
Alhamany Z; El Mzibri M; Kharbach A; Malihy A; Abouqal R; Jaddi H; Benomar A; Attaleb M; Lamalmi N; Cherradi N
J Infect Dev Ctries; 2010 Nov; 4(11):732-9. PubMed ID: 21252451
[TBL] [Abstract][Full Text] [Related]
34. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer.
Nieminen P; Vuorma S; Viikki M; Hakama M; Anttila A
BJOG; 2004 Aug; 111(8):842-8. PubMed ID: 15270934
[TBL] [Abstract][Full Text] [Related]
35. Detection of human papillomavirus DNA in routine cervical scraping samples: use for a national cervical cancer screening program in a developing nation.
Othman N; Othman NH
Asian Pac J Cancer Prev; 2014; 15(5):2245-9. PubMed ID: 24716964
[TBL] [Abstract][Full Text] [Related]
36. Assessment of a new low-cost, PCR-based strategy for high-risk human papillomavirus DNA detection for cervical cancer prevention.
Surriabre P; Torrico A; Vargas T; Ugarte F; Rodriguez P; Fontaine V
BMC Infect Dis; 2019 Oct; 19(1):842. PubMed ID: 31615443
[TBL] [Abstract][Full Text] [Related]
37. ThinPrep cytology combined with HPV detection in the diagnosis of cervical lesions in 1622 patients.
Husaiyin S; Jiao Z; Yimamu K; Maisaidi R; Han L; Niyazi M
PLoS One; 2021; 16(12):e0260915. PubMed ID: 34855928
[TBL] [Abstract][Full Text] [Related]
38. Bethesda 2014 Implementation and Human Papillomavirus Primary Screening: Practices of Laboratories Participating in the College of American Pathologists PAP Education Program.
Davey DD; Souers RJ; Goodrich K; Mody DR; Tabbara SO; Booth CN
Arch Pathol Lab Med; 2019 Oct; 143(10):1196-1202. PubMed ID: 31021657
[TBL] [Abstract][Full Text] [Related]
39. Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs.
Lörincz AT; Richart RM
Arch Pathol Lab Med; 2003 Aug; 127(8):959-68. PubMed ID: 12873167
[TBL] [Abstract][Full Text] [Related]
40. Surgical staging identified false HPV-negative cases in a large series of invasive cervical cancers.
Petry KU; Liebrich C; Luyten A; Zander M; Iftner T
Papillomavirus Res; 2017 Dec; 4():85-89. PubMed ID: 29179875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
